Clinical research progress of T-DM1 in breast cancer

VernacularTitle:恩美曲妥珠单抗在乳腺癌中的临床研究进展
Author: Lixi LI ¹ ; Fei MA
Author Information

1. 国家癌症中心　国家肿瘤临床医学研究中心　中国医学科学院北京协和医学院肿瘤医院肿瘤内科　100021
Keywords: Breast neoplasms; Human epidermal growth factor receptor 2; Antibody-drug conjugate; Ado-trastuzumab emtansine
From: Chinese Journal of Oncology 2021;43(1):92-97
CountryChina
Language:Chinese
Abstract: Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) composed of trastuzumab, a linker, and a microtubule inhibitor. T-DM1 combines the highly effective targeting of antibody with the high anti-tumor activity of cytotoxic drugs, while reduces the off-target toxic side effects of cytotoxic drugs. T-DM1 has been applied in neoadjuvant therapy of HER2-positive breast cancer and rescue treatment of advanced breast cancer, greatly improves the prognosis of breast cancer patients. More and more clinical trials of T-DM1 for HER2 breast cancer and other solid tumors are ongoing, and more positive results are expected.